N-(8-Piperazin-1-yl-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetamide | 444620-68-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(8-Piperazin-1-yl-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetamide
• 英文别名: N-(8-piperazin-1-yl-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide
• CAS: 444620-68-2
• 化学式: C₁₆H₂₃N₃O
• 分子量: 273.378
• InChiKey: FUHRMGJITOPUFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(8-Piperazin-1-yl-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetamide 在 氢气 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 生成 (R)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-2-[4-(7-acetylamino-5,6,7,8-tetrahydro-naphthalen-1-yl)-piperazin-1-yl]-1-(4-chloro-benzyl)-2-oxo-ethyl]-amide
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035
• 作为产物：
  描述：

  4-(7-Acetylamino-5,6,7,8-tetrahydro-naphthalen-1-yl)-piperazine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 生成 N-(8-Piperazin-1-yl-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetamide
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035

文献信息

• [EN] SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES<br/>[FR] DERIVES DE 1,2,3,4-TETRAHYDRONAPHTHALENE SUBSTITUES
  申请人：ASTRA AKTIEBOLAG

  公开号：WO1997034883A1

  公开（公告）日：1997-09-25

  (EN) New piperidinyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having formula (I) wherein X is N or CH; Y is NR2CH2, CH2-NR2, NR2-CO, CO-NR2 or NR2SO2; R1 is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, where aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; as (R)-enantiomer, (S)-enantiomer or a racemate in the form of the free base or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical formulation containing the compounds, use of the compounds in the treatment of 5-hydroxytryptamine mediated disorders, processes for the preparation of the compounds and intermediates for the preparation of the compounds.(FR) Nouveaux dérivés de 1,2,3,4-tétrahydronaphthalène substitués par pipéridinyle ou pipérazinyle, de la formule (I). Dans cette formule, X est N ou CH; Y est NR2CH2, CH2-NR2, NR2-CO, CO-NR2 ou NR2SO2; R1 est H, C1-C6 alkyle ou C3-C6 cycloalkyle; R3 est C1-C6 alkyle, C3-C6 cycloalkyle ou (CH2)n-aryle, où aryle est phényle ou un cycle hétéroaromatique renfermant un ou deux hétéroatomes choisis parmi N, O et S et pouvant être mono- ou di-substitués; n est un nombre de 0 à 4; en tant qu'énantiomère (R), énantiomère (S) ou mélange racémique sous forme de base libre, de sel pharmaceutiquement acceptable ou d'hydrate de ce sel; formulation pharmaceutique renfermant ces composés, utilisation de ces composés pour le traitement des désordres à médiation de 5-hydroxytryptamine, procédés d'élaboration de ces composés et intermédiaires de ceux-ci.

  （中文翻译）具有以下化学式（I）的新的哌啶基或哌嗪基取代的1,2,3,4-四氢萘衍生物，其中X为N或CH; Y为NR2CH2，CH2-NR2，NR2-CO，CO-NR2或NR2SO2; R1为H，C1-C6烷基或C3-C6环烷基; R3为C1-C6烷基，C3-C6环烷基或（CH2）n-芳基，其中芳基为苯基或含有N，O和S中的一个或两个杂原子的杂环芳基，可以是单取代或双取代; n为0-4; 作为（R）对映体，（S）对映体或以自由碱、药物可接受的盐或其水合物的形式的混合物; 包含这些化合物的制药配方，用于治疗5-羟色胺介导的疾病，制备这些化合物的方法以及用于制备这些化合物的中间体。
• SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP0888319B1

  公开（公告）日：2003-01-29
• US6124283A
  申请人：——

  公开号：US6124283A

  公开（公告）日：2000-09-26
• US6410530B1
  申请人：——

  公开号：US6410530B1

  公开（公告）日：2002-06-25
• Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines
  作者：Matthew J. Fisher、Ryan T. Backer、Saba Husain、Hansen M. Hsiung、Jeffrey T. Mullaney、Thomas P. O’Brian、Paul L. Ornstein、Roger R. Rothhaar、John M. Zgombick、Karin Briner

  DOI：10.1016/j.bmcl.2005.07.035

  日期：2005.10

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.